Get the Stockscreener App
2.37
0.42%
-0.010
Annovis Bio Inc stock is traded at $2.37, with a volume of 345.80K.
It is down -0.42% in the last 24 hours and down -7.78% over the past month.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
See More
Previous Close:
$2.38
Open:
$2.37
24h Volume:
345.80K
Relative Volume:
0.83
Market Cap:
$46.18M
Revenue:
-
Net Income/Loss:
$-30.26M
P/E Ratio:
-1.1618
EPS:
-2.04
Net Cash Flow:
$-24.69M
1W Performance:
-13.50%
1M Performance:
-7.78%
6M Performance:
+11.27%
1Y Performance:
-74.21%
1-Day Range:
$2.35
$2.49
1-Week Range:
$2.32
$2.76
52-Week Range:
$1.11
$10.54
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.37 | 52.42M | 0 | -30.26M | -24.69M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
Annovis Bio Reports Q2 2025 Progress and Financials - TipRanks
Annovis Bio Secures Full Patent Protection for New Crystal Form of Alzheimer’s Drug Buntanetap - MSN
Michelle Chen named CEO of gene therapy play Form Bio - BioCentury
Quant Strategy Flags Annovis Bio Inc. for Entry2025 Earnings Impact & Technical Confirmation Alerts - newsyoung.net
Annovis Bio Advances Alzheimer’s Phase 3 Trial, Strengthens IP Portfolio - MSN
What makes Annovis Bio Inc. stock price move sharplyGap Up & Safe Capital Investment Plans - thegnnews.com
Annovis Bio appoints CEO as acting CFO following executive resignation By Investing.com - Investing.com India
Annovis Bio appoints CEO as acting CFO following executive resignation - Investing.com
Annovis Bio Inc. Rebound Backed by Sentiment ShiftJuly 2025 Catalysts & Reliable Intraday Trade Plans - beatles.ru
Annovis Bio’s Promising Alzheimer’s Drug Trial: What Investors Need to Know - TipRanks
Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results - GlobeNewswire
Annovis Bio Q2 Earnings: EPS Loss Narrows, No Revenue Reported, Cash and Cash Equivalents Rise to $17.1 Million - AInvest
ANNOVIS BIO -REDH Earnings Results: $ANVS Reports Quarterly Earnings - Quiver Quantitative
Annovis Reports Q2 2025 Financial Results, Drives Enrollment for Phase 3 AD Trial - AInvest
Annovis Bio, Inc. SEC 10-Q Report - TradingView
Annovis Advances Alzheimer's Phase 3 Trial With 76 Sites, Reports Stronger Cash Position - Stock Titan
Annovis Bio Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Annovis Bio ANVS Q2 2025 Earnings Preview Upside Potential on Strategic Innovations - AInvest
How sensitive is Annovis Bio Inc. to inflationTechnical Confluence Stock Ideas - mustnews.co.kr
RSI Reset May Fuel Rebound in Annovis Bio Inc.Weekly Stock Watch With Growth Focus Expanded - beatles.ru
Annovis Bio completes full patent transfer to crystal buntanetap - TipRanks
Annovis Completes Full Patent Transfer to Crystal Buntanetap - Santé log
Annovis secures IP protection for both forms of buntanetap By Investing.com - Investing.com Australia
Annovis secures IP protection for both forms of buntanetap - Investing.com India
Annovis Locks Down Patent Protection Until 2046 for Promising Alzheimer's and Parkinson's Treatment - Stock Titan
Bullish Candlestick Pattern Forms in Annovis Bio Inc.Real Time Alerts Based on AI Prediction Triggered - metal.it
How many analysts rate Annovis Bio Inc. as a “Buy”Achieve rapid financial growth with expert picks - Jammu Links News
What are analysts’ price targets for Annovis Bio Inc. in the next 12 monthsAccelerated earnings growth - Jammu Links News
What are Annovis Bio Inc. company’s key revenue driversFree Trend-Following Techniques - Jammu Links News
How does Annovis Bio Inc. compare to its industry peersMassive portfolio appreciation - Jammu Links News
Is Annovis Bio Inc. stock overvalued or undervaluedRapid growth trajectories - Jammu Links News
How volatile is Annovis Bio Inc. stock compared to the marketGrow your wealth steadily and securely - Jammu Links News
Why is Annovis Bio Inc. stock attracting strong analyst attentionUnlock powerful portfolio optimization tools - Jammu Links News
Recovery Setup Building in Annovis Bio Inc. Experts SayStrong Buy With Technical Confidence Supported - metal.it
Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection - 富途牛牛
What catalysts could drive Annovis Bio Inc. stock higher in 2025Swing Trade Insights With Proven Results - Jammu Links News
Will Annovis Bio Inc. Stock Benefit from AI and Green Energy TrendsTrade Scanner With Buy Zone Alerts Flagged - metal.it
Annovis Bio Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingTrade Insight With Community Collaboration Supported - metal.it
Will Annovis Bio Inc. stock split in the near futureChart-Based Trade Entries Gain Analyst Support - metal.it
What is Annovis Bio Inc. company’s growth strategyMaximize your returns with expert insights - Jammu Links News
Should I hold or sell Annovis Bio Inc. stock in 2025Accelerated capital growth - Jammu Links News
Is Annovis Bio Inc. a growth stock or a value stockConsistently exceptional gains - Jammu Links News
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):